HORIZON EUROPE
Europeo
Specific Challenge:Nuclear and ionising radiation technologies have a central place in modern medicine, saving lives and improving the quality of life for patients. In the EU alone, each citizen will undergo on average at least one medical procedure involving ionising radiation each year. This includes a wide variety of diagnostic tests – from simple dental or chest x-rays, through mass screening for female breast cancer, to molecular and advanced imaging, such as positron emission tomography (PET), computed tomography (CT) or hybrid imaging. Radiological imaging is also an integral component of minimally invasive interventional procedures, for example in cardiology and vascular treatments. Radiotherapy is an indispensable tool in the fight against cancer used in about half of the cancer patients in Europe.
The medical applications of ionising radiation have also significant growth and jobs potential. The EUR 20 billion global market of medical radiological equipment has an annual growth of at least 3%. In Europe alone, more than 700,000 healthcare workers are involved in medical procedures using ionising radiation. At least 60,000 people are directly employed by the m...
ver más
Specific Challenge:Nuclear and ionising radiation technologies have a central place in modern medicine, saving lives and improving the quality of life for patients. In the EU alone, each citizen will undergo on average at least one medical procedure involving ionising radiation each year. This includes a wide variety of diagnostic tests – from simple dental or chest x-rays, through mass screening for female breast cancer, to molecular and advanced imaging, such as positron emission tomography (PET), computed tomography (CT) or hybrid imaging. Radiological imaging is also an integral component of minimally invasive interventional procedures, for example in cardiology and vascular treatments. Radiotherapy is an indispensable tool in the fight against cancer used in about half of the cancer patients in Europe.
The medical applications of ionising radiation have also significant growth and jobs potential. The EUR 20 billion global market of medical radiological equipment has an annual growth of at least 3%. In Europe alone, more than 700,000 healthcare workers are involved in medical procedures using ionising radiation. At least 60,000 people are directly employed by the medical equipment manufacturers which includes EU-based industrial champions and also many SMEs.
The medical applications of ionising radiation experience rapid development, both on the diagnostic and therapeutic side. Modern imaging and therapy are constantly progressing and technologies become more complex. There is a trend towards integrating different imaging modalities, diagnosis and treatment and move towards precision and personalised medicine.
This dynamic environment calls for the development of a co-ordinated and systematic European approach to research and innovation in medical applications of ionising radiation, with the aim to improve patient care and quality of life of the EU citizens, support growth and jobs in the EU and to improve the EU’s position on the global market. The action in this area should be informed by, and co-ordinated with, other Commission work on non-power applications of ionising radiation[1].
Scope:This action should prepare a Strategic Research Agenda (SRA) for research on medical applications of ionising radiation during with the objective of ensuring synergies between the 'Health' cluster of the Horizon Europe Framework Programme for Research and Innovation and the Euratom Research and Training Programme 2021-2025[2]. Inputs and active involvement of European stakeholders from the clinical, industrial, regulatory, scientific and all other relevant fields should be ensured through their inclusion in the project consortium, by organising dedicated events, workshops and by any other relevant ways of involvement.
Building upon the preparatory activities towards a Strategic agenda for non-power applications [https://ec.europa.eu/info/events/addressing-societal-challenges-through-advancing-medical-industrial-and-research-applications-nuclear-and-radiation-technology-2018-mar-20_en , this action should:
Analyse the research needs for the development and delivery of high-quality healthcare for the European citizens including, but not limited to, the long-term supply of radioisotopes, quality and safety of medical applications of ionising radiation and facilitating innovation in medical therapies and imaging involving ionising radiation.Identify the key needs and actions for European research into the medical applications of ionising radiation including diagnostic and therapeutic applications of x-rays, particle accelerators, radioisotopes and research reactors.Identify the needs for European research to support innovation in further medical applications, such as photon, proton and heavy ion radiotherapy, molecular radiotherapy and theranostics, image guided radiotherapy, advanced and hybrid diagnostic imaging, health screening etc.The SRA section on medical radioisotopes should examine the possibility (including advantages and drawbacks) for establishing a European centre of excellence for research into new or improved radioisotope therapies and diagnostic tests as well as into new or improved methods for production of radioisotopes. Other areas of research, e.g. relating to the security of supply of radioisotopes, may also be covered.Identify needs and actions, strengths and weaknesses of European research actors in respect to the various aforementioned fields.Analyse and propose actions, if needed, regarding the EU education and training capabilities and future needs related to the various aforementioned fields.Propose a way forward towards integrating radiation protection and safety aspects of medical applications into a broader framework of quality and safety in healthcare. Aspects relating to clinical research, equipment and drugs authorisation, development and implementation of clinical guidance, equipment quality control and dose measurement, use of e-Health systems, etc. should be examined. The SRA should also consider improvements to protection of staff, patients, carers, the public and the environment in medical installations against adverse effects of radiation. In this context, the SRA should take account of the existing research agendas[3] and Euratom actions[4] on radiation protection in medicine, as well as the principles of radiation protection defined by Council Directive 2013/59/Euratom.
The Commission considers that proposals requesting a contribution from the Euratom Programme up to EUR 2.0 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected Impact:The SRA for research into the medical applications of ionising radiation will provide guidance to stakeholders and the Commission on the steps needed in the coming decades for the development of research activities and knowledge in this area.
[1]https://ec.europa.eu/info/events/addressing-societal-challenges-through-advancing-medical-industrial-and-research-applications-nuclear-and-radiation-technology-2018-mar-20_en
[2]As defined in the Commission proposals for Horizon Europe and Euratom research programmes, COM(2018) 435 and COM(2018) 437
[3]As those developed by the EURAMED and EURADOS platforms.
[4]E.g. the MEDIRAD research project, http://www.medirad-project.eu/.
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Características de la financiación
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in part B and part C of the General Annexes of the Work Programme.
Personnel costs related to the work performed on the action by PhD students, postdoctoral researchers and trainees is considered to be part of education and training activities.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in part G of the General Annexes of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in part B and part C of the General Annexes of the Work Programme.
Personnel costs related to the work performed on the action by PhD students, postdoctoral researchers and trainees is considered to be part of education and training activities.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in part G of the General Annexes of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
6. Additional provisions:
Horizon 2020 budget flexibility - part H of the General Annexes of the Work Programme
Classified information - part I of the General Annexes of the Work Programme
Technology readiness levels (TRL) - part F of the General Annexes of the Work Programme – where a topic description refers to TRL, these definitions apply
Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.
7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in part K of the General Annexes of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
8. Additional documents:
Euratom Work Programme 2019-20
Legal basis: Euratom Research and Training Programme 2019-2020
Legal basis: Horizon 2020 Rules for Participation
Información adicional de la convocatoria
Otras ventajas
Ayudas Similares
| Abierta
| Próximamente
| Abierta